Fulgent Genetics, Inc. (FLGT)
FLGTNASDAQ-GMMedical Specialities
$25.71
-0.4450 (-1.70%) today
Regular session, Nov 10, 3:06 PM ET
- Market cap
- $718.17m
- P/E
- –
- EPS, last 4 quarters
- $-2.01
- Dividend yield
- –
- Day range
- $25.53 to $27.41
- 52-week range
- $13.46 to $31.04
- Average volume
- 333.7k
- Previous close
- $26.15
Analysts
1 coveringHold0 buy, 1 hold, 0 sell
Targets a year out average $25.00, -2.7% from here
Earnings
next estimate $-1.01Next report
Dec 2025
+59.3%
Mar 2026
-20.8%
Jun 2026
-11.4%
Sep 2026
+62.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $83.34m | $71.14m | $85.39m | $90.41m |
| Gross profit | $32.58m | $21.49m | $25.68m | $31.95m |
| Operating income | -$36.24m | -$34.62m | -$36.07m | -$22.55m |
| Net income | -$23.42m | -$24.83m | -$29.53m | -$13.15m |
Last four quarters: revenue $330.27m, margin -27.5%, free cash flow -$1.40m
News
8 latest- Fulgent Genetics (FLGT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- What Fulgent Genetics (FLGT) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?Zacks · Sep 22, 2026
- Think Outside the Box With These 3 Companies That Make Unusual Business Models WorkMarketBeat · Sep 21, 2026
- Fulgent Genetics (FLGT) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 7, 2026
- Noteworthy Friday Option Activity: OSG, FLGT, LQDABNK Invest · Jul 31, 2026
- Fulgent Genetics Q2 Earnings Call HighlightsMarketBeat · Jul 30, 2026
The company
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent's laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent's therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- fulgentgenetics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.